NCT05450549View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

June 8, 2023

Study Completion Date

June 8, 2023

Conditions
Healthy Participant
Interventions
DRUG

DNL919

Single doses

DRUG

Placebo

Single doses

Trial Locations (1)

2333

Centre for Human Drug Research (CHDR), Leiden

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Denali Therapeutics Inc.

INDUSTRY

NCT05450549 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants | Biotech Hunter | Biotech Hunter